Mesial temporal lobe epilepsy with hippocampal sclerosis
MONDO:0020476Mesial temporal lobe epilepsy with hippocampal sclerosis is a rare epilepsy syndrome defined by seizures originating in limbic areas of the mesial temporal lobe, particularly in the hippocampus, amygdala, and in the parahippocampal gyrus and its connections, and hippocampal sclerosis, usually unilateral or asymmetric. It is frequently associated with an initial precipitating event, such as febrile seizures, hypoxia, intracranial infection or head trauma, most often occurring in the first five years of life, followed by a latent period without seizures. Typical seizures consist of a characteristic aura that is frequently a rising epigastric sensation associated with emotional disturbances, illusions, and autonomic symptoms (widened pupils, palpitations), progressive impairment of consciousness, oro-alimentary automatisms (lip smacking, chewing, licking, tooth grinding), behavioral arrest, head deviation, dystonic postures, hand and verbal automatisms. Seizures are followed by postictal dysfunction. Initially, seizures are easily controlled with antiepileptic drugs, later they frequently become refractory and associated with progressive behavioral changes and memory deficits.
Also known as: MTLE-HS
20 clinical trials for this condition and its sub-types, 10 tagged with Mesial temporal lobe epilepsy with hippocampal sclerosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Gene therapy breakthrough targets severe epilepsy in first human trial
Disease control Recruiting nowThis early-stage study tests a new gene therapy called AMT-260 in 12 adults with a severe form of epilepsy that doesn't respond to standard medications. The treatment is delivered directly into the brain using MRI guidance. The main goals are to check safety and see if it can red…
Phase 1/2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Brain cell transplant shows promise for Tough-to-Treat epilepsy
Disease control Recruiting nowThis study tests a one-time injection of lab-grown nerve cells (NRTX-1001) into the brain for people with a specific type of epilepsy that doesn't respond to medication. The cells are designed to release a calming chemical called GABA to quiet overactive brain signals. Researcher…
Phase 3 • Sponsor: Neurona Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Brain pacemaker aims to quiet seizures and boost memory
Disease control Recruiting nowThis study tests a personalized deep brain stimulation (DBS) method for people with epilepsy that starts in the memory center of the brain. Eight participants will receive a device that sends low-frequency electrical pulses to specific brain networks, with the goal of reducing se…
Sponsor: Nitin Tandon • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Brain cell injection aims to tame seizures in Drug-Resistant epilepsy
Disease control Recruiting nowThis early-phase trial tests an injection of special brain cells (GABAergic interneuron progenitors) in 6 adults with drug-resistant mesial temporal lobe epilepsy. The goal is to see if the treatment is safe and can reduce seizure frequency. Participants will receive the cell the…
Early phase 1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Zapping seizures away: laser treatment offers new hope for epilepsy patients
Disease control Recruiting nowThis study tests a minimally invasive laser treatment for people with drug-resistant temporal lobe epilepsy. The procedure uses heat from a laser to destroy the small part of the brain causing seizures. Researchers will track whether patients become seizure-free and how their mem…
Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Brain cell injection could tame epilepsy seizures
Disease control Recruiting nowThis early-stage trial tests a one-time injection of special nerve cells (NRTX-1001) into both sides of the brain in 10 adults with drug-resistant epilepsy. The cells are designed to calm overactive brain signals by releasing GABA. The main goal is safety, but researchers will al…
Phase 1/2 • Sponsor: Neurona Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC